A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin
A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
Participants must also be taking metformin and glimepiride.